
- <Centre d'Information et de documentation du CRA Rhône-Alpes
- CRA
- Informations pratiques
		- 
						Adresse
						Centre d'information et de documentation Horaires
 du CRA Rhône-Alpes
 Centre Hospitalier le Vinatier
 bât 211
 95, Bd Pinel
 69678 Bron CedexLundi au Vendredi Contact
 9h00-12h00 13h30-16h00Tél: +33(0)4 37 91 54 65 Mail
 Fax: +33(0)4 37 91 54 37
 
- 
						Adresse
						
Auteur Barbara R. POBER
|  | 
Documents disponibles écrits par cet auteur (1)
 
                
             
            
                
                     
                
             
						
					
						
							 Faire une suggestion  Affiner la recherche
						
					   Faire une suggestion  Affiner la rechercheBuspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series / Robyn P. THOM in Journal of Autism and Developmental Disorders, 50-2 (February 2020)

Titre : Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series Type de document : texte imprimé Auteurs : Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J MCDOUGLE, Auteur Article en page(s) : p.676-682 Langues : Anglais (eng) Mots-clés : Anxiety Buspirone Williams syndrome Index. décimale : PER Périodiques Résumé : Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS. En ligne : http://dx.doi.org/10.1007/s10803-019-04301-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416 
in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682[article] Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series [texte imprimé] / Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J MCDOUGLE, Auteur . - p.676-682.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682
Mots-clés : Anxiety Buspirone Williams syndrome Index. décimale : PER Périodiques Résumé : Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS. En ligne : http://dx.doi.org/10.1007/s10803-019-04301-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416 

